A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.

Celebrating lab techs; Myriad settles suits; publish in top-tier journals or perish

A judge declines Myriad Genetics’s request to block its competitors from selling BRCA tests.  

On the gene patent decision; a high-res human brain model; bats’ influence on moths mating calls; toxicants threaten brain health; platelet-driven immunity

The scientific community and the impact of the Myriad Genetics Supreme Court decision

Supreme Court says no patenting (natural) genes; brain-computer interfaces mimic motor learning in brain; regenerating finger tips; gene therapy goes deeper; NIH needs more diversity; cross-border collaboration

The Supreme Court agrees to hear a case deciding if two cancer genes should continue to be protected by patent.

Myriad Genetics can hold patents on the BRAC1 and BRAC2 oncogenes, but not on tests comparing DNA sequences.

James Watson files a brief in the ongoing legal case over Myriad Genetics’ right to hold patents on the BRCA1 and BRCA2 genes.

A public interest legal group has renewed the fight against DNA patenting.

Two key patent cases that no doubt will impact the future of personalized medicine are pending review by the US Supreme Court. What will the Court decide?

The case challenging the right of a healthcare company to patent cancer genes may make it all the way to the US Supreme Court.

A US federal appeals court says human genes are patentable.

Legal battles over gene patents and uncooperative patent holders threaten the widespread implementation of personalized medicine.